IDYA
IDEAYA Biosciences, Inc.
Price Chart
Latest Quote
$36.28
+1.37 (+3.92%)
Current Price
| Previous Close | $34.91 |
| Open | $35.47 |
| Day High | $37.18 |
| Day Low | $35.11 |
| Volume | 2,125,321 |
Stock Information
| Shares Outstanding | 96.27M |
| Total Debt | $28.60M |
| Cash Equivalents | $671.20M |
| Revenue | $225.27M |
| Net Income | $-140.06M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.49B |
| EPS (TTM) | $-1.57 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.54B |
| Sales | $225.27M |
| Income | $-140.06M |
| Book/sh | $10.67 |
| Cash/sh | $6.97 |
| Employees | 145 |
Financial Ratios
| Quick Ratio | 10.45 |
| Current Ratio | 10.74 |
| Debt/Eq | 3.05 |
Returns & Margins
| ROA | -10.76% |
| ROE | -14.28% |
| Gross Margin | -50.73% |
| Operating Margin | -1654.63% |
| Profit Margin | -62.17% |
Ownership
| Insider Ownership | 2.22% |
| Institutional Ownership | 101.79% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -9.92 |
| P/S | 15.51 |
| P/B | 3.40 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $52.79 |
Technical Indicators
| SMA20 | $30.22 |
| SMA50 | $29.95 |
| SMA200 | $31.35 |
| RSI | 72.44 |
| ATR | 2.0046 |
| Shares Float | 86.96M |
| Short Float | 15.23% |
| Short Ratio | 14.31 |
| Volatility | -0.05 |
| Rel Volume | 1.61 |
Performance History
| Week | +18.68% |
| Month | +24.67% |
| Quarter | +18.83% |
| 6 Months | +8.14% |
| YTD | +7.18% |
| Year | +69.37% |
| 3 Years | +50.73% |
| 5 Years | +65.44% |
| 10 Years | +224.22% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $36.28 | 2,256,000 |
| 2026-06-23 | $34.91 | 1,743,700 |
| 2026-06-22 | $34.23 | 1,670,600 |
| 2026-06-18 | $31.23 | 2,018,500 |
| 2026-06-17 | $31.26 | 937,800 |
| 2026-06-16 | $30.57 | 1,168,300 |
| 2026-06-15 | $30.23 | 1,247,600 |
| 2026-06-12 | $28.98 | 617,100 |
| 2026-06-11 | $28.84 | 1,361,700 |
| 2026-06-10 | $27.60 | 1,559,400 |
| 2026-06-09 | $28.07 | 4,244,100 |
| 2026-06-08 | $31.48 | 2,580,800 |
| 2026-06-05 | $28.29 | 710,900 |
| 2026-06-04 | $29.22 | 687,700 |
| 2026-06-03 | $28.40 | 1,067,300 |
| 2026-06-02 | $27.87 | 948,100 |
| 2026-06-01 | $28.94 | 873,000 |
| 2026-05-29 | $29.47 | 1,097,800 |
| 2026-05-28 | $29.34 | 584,500 |
| 2026-05-27 | $29.28 | 577,200 |
| 2026-05-26 | $29.35 | 590,700 |
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
đ° Latest News
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study
Insider Monkey âĸ 2026-06-11T10:20:33Z
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results
Barchart âĸ 2026-06-09T13:29:51Z
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Inflation Data
MT Newswires âĸ 2026-06-09T13:04:06ZWhat IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders
Simply Wall St. âĸ 2026-06-06T10:08:46Z
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
MarketBeat âĸ 2026-05-26T23:03:46Z
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
MarketBeat âĸ 2026-05-25T11:07:47Z
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data
MarketBeat âĸ 2026-05-18T04:05:29Z
Assessing IDEAYA Biosciences (IDYA) Valuation After Positive Darovasertib Phase 2/3 Results And FDA Real-Time Review
Simply Wall St. âĸ 2026-05-07T19:17:55Z
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-05T11:10:02Z
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-05-03T18:41:23Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $218,710,000 | $7,000,000 | $23,385,000 | $50,931,000 |
| Operating Revenue | $218,710,000 | $7,000,000 | $23,385,000 | $50,931,000 |
| Expenses | ||||
| Total Expenses | $378,023,000 | $333,975,000 | $157,814,000 | $113,433,000 |
| Net Non Operating Interest Income Expense | $45,615,000 | $52,498,000 | $21,468,000 | $3,847,000 |
| Operating Expense | $378,023,000 | $333,975,000 | $157,814,000 | $113,433,000 |
| General And Administrative Expense | $63,319,000 | $39,302,000 | $28,306,000 | $23,897,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Net Interest Income | $45,615,000 | $52,498,000 | $21,468,000 | $3,847,000 |
| Interest Income | $45,615,000 | $52,498,000 | $21,468,000 | $3,847,000 |
| Normalized Income | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Net Income From Continuing And Discontinued Operation | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Total Operating Income As Reported | $-159,313,000 | $-326,975,000 | $-134,429,000 | $-62,502,000 |
| Net Income Common Stockholders | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Net Income | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Net Income Including Noncontrolling Interests | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Net Income Continuous Operations | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Pretax Income | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Interest Income Non Operating | $45,615,000 | $52,498,000 | $21,468,000 | $3,847,000 |
| Operating Income | $-159,313,000 | $-326,975,000 | $-134,429,000 | $-62,502,000 |
| Per Share | ||||
| Diluted EPS | $-1.28 | $-3.36 | $-1.96 | $-1.42 |
| Basic EPS | $-1.28 | $-3.36 | $-1.96 | $-1.42 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-154,720,000 | $-323,141,000 | $-130,421,000 | $-58,987,000 |
| Reconciled Depreciation | $4,593,000 | $3,834,000 | $4,008,000 | $3,515,000 |
| EBITDA (Bullshit earnings) | $-154,720,000 | $-323,141,000 | $-130,421,000 | $-58,987,000 |
| EBIT | $-159,313,000 | $-326,975,000 | $-134,429,000 | $-62,502,000 |
| Diluted Average Shares | $88,485,238 | $81,678,069 | $57,519,929 | $41,444,696 |
| Basic Average Shares | $88,485,238 | $81,678,069 | $57,519,929 | $41,444,696 |
| Diluted NI Availto Com Stockholders | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Research And Development | $314,704,000 | $294,673,000 | $129,508,000 | $89,536,000 |
| Selling General And Administration | $63,319,000 | $39,302,000 | $28,306,000 | $23,897,000 |
| Other Gand A | $63,319,000 | $39,302,000 | $28,306,000 | $23,897,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $2,159,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Total Assets | $1,109,324,000 | $1,124,091,000 | $649,316,000 | $387,969,000 |
| Total Non Current Assets | $442,597,000 | $434,378,000 | $116,684,000 | $17,515,000 |
| Other Non Current Assets | $1,015,000 | $805,000 | $782,000 | $205,000 |
| Investmentin Financial Assets | $410,297,000 | $405,832,000 | $107,492,000 | $8,317,000 |
| Current Assets | $666,727,000 | $689,713,000 | $532,632,000 | $370,454,000 |
| Other Current Assets | $21,366,000 | $13,394,000 | $7,500,000 | $5,414,000 |
| Receivables | $5,973,000 | $0 | $18,000 | $211,000 |
| Other Receivables | $5,973,000 | - | - | - |
| Cash Cash Equivalents And Short Term Investments | $639,388,000 | $676,319,000 | $525,114,000 | $364,829,000 |
| Cash And Cash Equivalents | $112,825,000 | $84,378,000 | $157,018,000 | $68,632,000 |
| Accounts Receivable | - | $3,000 | $18,000 | $211,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $27,914,000 | $19,171,000 | $2,872,000 | $3,482,000 |
| Long Term Debt And Capital Lease Obligation | $27,575,000 | $18,873,000 | $1,125,000 | $1,611,000 |
| Current Debt And Capital Lease Obligation | $339,000 | $298,000 | $1,747,000 | $1,871,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $86,390,000 | $64,944,000 | $28,226,000 | $38,514,000 |
| Total Non Current Liabilities Net Minority Interest | $27,575,000 | $18,873,000 | $1,125,000 | $6,796,000 |
| Current Liabilities | $58,815,000 | $46,071,000 | $27,101,000 | $31,718,000 |
| Payables And Accrued Expenses | $58,476,000 | $45,773,000 | $25,354,000 | $21,279,000 |
| Payables | $17,584,000 | $15,421,000 | $6,598,000 | $4,280,000 |
| Accounts Payable | $17,584,000 | $15,421,000 | $6,598,000 | $4,280,000 |
| Non Current Deferred Liabilities | - | - | $0 | $5,185,000 |
| Current Deferred Liabilities | - | - | $0 | $8,568,000 |
| Equity | ||||
| Common Stock Equity | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Total Equity Gross Minority Interest | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Stockholders Equity | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Gains Losses Not Affecting Retained Earnings | $2,267,000 | $812,000 | $562,000 | $-2,871,000 |
| Other Equity Adjustments | $2,267,000 | $812,000 | $562,000 | $-2,871,000 |
| Retained Earnings | $-736,539,000 | $-622,841,000 | $-348,364,000 | $-235,403,000 |
| Other | ||||
| Ordinary Shares Number | $87,796,561 | $86,503,509 | $65,039,369 | $48,193,179 |
| Share Issued | $87,796,561 | $86,503,509 | $65,039,369 | $48,193,179 |
| Tangible Book Value | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Invested Capital | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Working Capital | $607,912,000 | $643,642,000 | $505,531,000 | $338,736,000 |
| Capital Lease Obligations | $27,914,000 | $19,171,000 | $2,872,000 | $3,482,000 |
| Total Capitalization | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Additional Paid In Capital | $1,757,197,000 | $1,681,167,000 | $968,885,000 | $587,724,000 |
| Capital Stock | $9,000 | $9,000 | $7,000 | $5,000 |
| Common Stock | $9,000 | $9,000 | $7,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $27,575,000 | $18,873,000 | $1,125,000 | $1,611,000 |
| Current Capital Lease Obligation | $339,000 | $298,000 | $1,747,000 | $1,871,000 |
| Current Accrued Expenses | $40,892,000 | $30,352,000 | $18,756,000 | $16,999,000 |
| Investments And Advances | $410,297,000 | $405,832,000 | $107,492,000 | $8,317,000 |
| Available For Sale Securities | $410,297,000 | $405,832,000 | $107,492,000 | $8,317,000 |
| Net PPE | $31,285,000 | $27,741,000 | $8,410,000 | $8,993,000 |
| Accumulated Depreciation | $-14,256,000 | $-11,711,000 | $-9,611,000 | $-7,553,000 |
| Gross PPE | $45,541,000 | $39,452,000 | $18,021,000 | $16,546,000 |
| Leases | $5,124,000 | $4,913,000 | $3,321,000 | $3,321,000 |
| Other Properties | $38,130,000 | $32,288,000 | $13,701,000 | $12,227,000 |
| Machinery Furniture Equipment | $2,287,000 | $2,251,000 | $999,000 | $998,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $526,563,000 | $591,941,000 | $368,096,000 | $296,197,000 |
| Treasury Shares Number | - | - | $0 | - |
| Non Current Deferred Revenue | - | - | $0 | $5,185,000 |
| Current Deferred Revenue | - | - | $0 | $8,568,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-73,466,000 | $-251,441,000 | $-117,592,000 | $-90,618,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-71,098,000 | $-247,584,000 | $-115,224,000 | $-87,175,000 |
| Cash Flow From Continuing Operating Activities | $-71,098,000 | $-247,584,000 | $-115,224,000 | $-87,175,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,368,000 | $-3,857,000 | $-2,368,000 | $-3,443,000 |
| Investing Cash Flow | $69,976,000 | $-502,559,000 | $-158,456,000 | $-33,404,000 |
| Cash Flow From Continuing Investing Activities | $69,976,000 | $-502,559,000 | $-158,456,000 | $-33,404,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $24,855,000 | $654,229,000 | $309,763,000 | $94,962,000 |
| Financing Cash Flow | $29,779,000 | $677,551,000 | $362,717,000 | $97,165,000 |
| Cash Flow From Continuing Financing Activities | $29,779,000 | $677,551,000 | $362,717,000 | $97,165,000 |
| Net Common Stock Issuance | $24,855,000 | $654,229,000 | $309,763,000 | $94,962,000 |
| Common Stock Issuance | $24,855,000 | $654,229,000 | $309,763,000 | $94,962,000 |
| Net Preferred Stock Issuance | - | $9,400,000 | $42,182,000 | $0 |
| Preferred Stock Issuance | - | $9,400,000 | $42,182,000 | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $25,000 | $69,000 | $60,000 |
| End Cash Position | $113,840,000 | $85,183,000 | $157,775,000 | $68,738,000 |
| Beginning Cash Position | $85,183,000 | $157,775,000 | $68,738,000 | $92,152,000 |
| Changes In Cash | $28,657,000 | $-72,592,000 | $89,037,000 | $-23,414,000 |
| Proceeds From Stock Option Exercised | $4,924,000 | $23,322,000 | $52,954,000 | $2,203,000 |
| Net Investment Purchase And Sale | $72,344,000 | $-498,702,000 | $-156,088,000 | $-29,961,000 |
| Sale Of Investment | $680,233,000 | $692,607,000 | $439,892,000 | $225,847,000 |
| Purchase Of Investment | $-607,889,000 | $-1,191,309,000 | $-595,980,000 | $-255,808,000 |
| Net PPE Purchase And Sale | $-2,368,000 | $-3,857,000 | $-2,368,000 | $-3,443,000 |
| Purchase Of PPE | $-2,368,000 | $-3,857,000 | $-2,368,000 | $-3,443,000 |
| Change In Working Capital | $1,868,000 | $11,546,000 | $-13,207,000 | $-42,969,000 |
| Change In Other Working Capital | $-5,973,000 | - | $-13,753,000 | $-46,479,000 |
| Change In Other Current Liabilities | $2,557,000 | $-1,369,000 | $-1,872,000 | $-1,699,000 |
| Change In Payables And Accrued Expense | $13,124,000 | $19,074,000 | $4,270,000 | $6,436,000 |
| Change In Accrued Expense | $10,427,000 | $10,794,000 | $1,635,000 | $4,572,000 |
| Change In Payable | $2,697,000 | $8,280,000 | $2,635,000 | $1,864,000 |
| Change In Account Payable | $2,697,000 | $8,280,000 | $2,635,000 | $1,864,000 |
| Change In Prepaid Assets | $-7,840,000 | $-6,159,000 | $-2,045,000 | $-2,119,000 |
| Change In Receivables | $0 | $0 | $193,000 | $892,000 |
| Changes In Account Receivables | $0 | $0 | $193,000 | $892,000 |
| Stock Based Compensation | $46,115,000 | $34,746,000 | $18,489,000 | $11,629,000 |
| Amortization Of Securities | $-9,976,000 | $-23,233,000 | $-11,553,000 | $-695,000 |
| Depreciation Amortization Depletion | $4,593,000 | $3,834,000 | $4,008,000 | $3,515,000 |
| Depreciation And Amortization | $4,593,000 | $3,834,000 | $4,008,000 | $3,515,000 |
| Depreciation | $4,593,000 | $3,834,000 | $4,008,000 | $3,515,000 |
| Net Income From Continuing Operations | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |
| Change In Other Current Assets | - | - | - | $1,414,000 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-06-24